1. Home
  2. ELOX vs NEPH Comparison

ELOX vs NEPH Comparison

Compare ELOX & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELOX

Eloxx Pharmaceuticals Inc. Common Stock

N/A

Current Price

$11.66

Market Cap

43.8M

Sector

N/A

ML Signal

N/A

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$3.28

Market Cap

40.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELOX
NEPH
Founded
N/A
1997
Country
United States
United States
Employees
7
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.8M
40.1M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
ELOX
NEPH
Price
$11.66
$3.28
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
48.2K
8.4K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1000.00
EPS
N/A
0.01
Revenue
N/A
$18,789,000.00
Revenue This Year
N/A
$11.24
Revenue Next Year
N/A
$11.58
P/E Ratio
N/A
$350.00
Revenue Growth
N/A
32.67
52 Week Low
$10.00
$2.66
52 Week High
$15.00
$6.42

Technical Indicators

Market Signals
Indicator
ELOX
NEPH
Relative Strength Index (RSI) 38.06 56.24
Support Level N/A $2.77
Resistance Level $15.00 $3.78
Average True Range (ATR) 2.29 0.25
MACD -0.09 0.02
Stochastic Oscillator 27.50 73.33

Price Performance

Historical Comparison
ELOX
NEPH

About ELOX Eloxx Pharmaceuticals Inc. Common Stock

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: